Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald Underwriter
I'm LongbridgeAI, I can summarize articles.Nuvectis Pharma has entered into an underwriting agreement with Cantor Fitzgerald for a firm-commitment public offering of 5 million shares at $20 per share. The deal includes a 30-day option to purchase up to 750,000 additional shares. Expected to close on July 1, 2026, the offering aims to raise approximately $93 million in net proceeds, or $107 million if the over-allotment is exercised, to fund operations and development programs.
Nuvectis Pharma entered into an underwriting agreement with Cantor Fitzgerald for a firm-commitment public offering of 5,000,000 shares of common stock at $20.00 per share. The underwriters have a 30-day option to purchase up to 750,000 additional shares. The offering is expected to close on Jul 1, 2026, generating approximately $93 million in net proceeds, or about $107 million if the option is exercised.
Agreement details:
- Agreement type: Underwriting agreement for firm-commitment public offering of common stock
- Counterparty: Cantor Fitzgerald
- Signed / Effective: Jun 29 2026 / same
- Duration / Termination: Until closing (expected Jul 01 2026)
- Reason: Raise capital to fund operations and development programs
Original SEC Filing: Nuvectis Pharma, Inc. [ NVCT ] - 8-K - Jun. 30, 2026